A5035535613- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Gut microbiota and health
- Neuroendocrine Tumor Research Advances
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Molecular Sensors and Ion Detection
- Epigenetics and DNA Methylation
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Nanoplatforms for cancer theranostics
- Spectroscopy and Chemometric Analyses
- Monoclonal and Polyclonal Antibodies Research
- Metastasis and carcinoma case studies
- Inflammatory Biomarkers in Disease Prognosis
- Gastrointestinal disorders and treatments
- Advanced Photocatalysis Techniques
Huazhong Agricultural University
2018-2025
China National Research Institute of Food and Fermentation
2022-2025
Shanghai Zhangjiang Laboratory
2025
Peking University Cancer Hospital
2015-2024
Peking University
2015-2024
Qufu Normal University
2021-2024
Henan Normal University
2024
Nanjing Tech University
2023-2024
Collaborative Innovation Center of Advanced Microstructures
2024
Nanjing University
2024
Abstract Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR cells showed promising efficacy against gastric cancer (GC) a preclinical study. Here we report interim analysis results an ongoing, open-label, single-arm, phase 1 clinical trial CLDN18.2-targeted (CT041) patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897...
To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, metastatic oesophageal squamous cell carcinoma.Multicentre, randomised, double blind, phase 3 trial.66 sites China and 13 outside between 14 December 2018 9 April 2021.659 adults (aged ≥18 years) advanced carcinoma who had not received systemic treatment.Participants were randomised 1:1 to receive...
We report on a comprehensive analysis of the gut microbiomes patients with gastrointestinal (GI) cancer receiving anti-PD-1/PD-L1 treatment. The human microbiota has been associated clinical responses to immunotherapy in melanoma, non-small cell lung cancer, and renal carcinoma. aimed investigate this association GI cancers. also identified bacterial taxa patient stratification potential. recruited 74 advanced-stage treatment collected their fecal samples prior during immunotherapy, along...
Although the antibody-drug conjugates (ADCs) have significantly improved survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, efficacy ADC used as a single agent is limited. Therefore, it necessary to investigate effective and safe combination regimens. Preclinical data indicated synergetic antitumour effect RC48 programmed cell death protein 1 (PD-1) inhibitors. We aimed evaluate safety plus toripalimab in...
infection is associated with the risk of gastrointestinal (GI) cancers; however, its impact on immunotherapy for GI cancers remains uncertain. In this study, we included 10,122 patients who underwent
245 Background: Inhibition of TIGIT, a novel checkpoint inhibitor, may further amplify immune responses by complementing the PD-L1/PD-1 pathway. Anti-tumor activity has been demonstrated with cancer immunotherapy in ESCC. SKYSCRAPER-08 (NCT04540211) is evaluating efficacy and safety tira (anti-TIGIT) + atezo (anti-PD-L1) combination CT compared placebo as 1L treatment (tx) an Asian population unresectable locally advanced (LA), recurrent, or metastatic (R/M) Methods: Eligible pts (confirmed...
This study was intended to determine the clinical significance of circulating tumour cells (CTCs) in patients with advanced gastric cancer (AGC), particularly potential role CTCs for dynamic monitoring therapeutic response.A single-centre, prospective undertaken 136 newly diagnosed AGC. The patients' were enumerated using CellSearch at baseline and first response evaluation. In 15 whose condition permitted longitudinal study, longitudinally during treatment.Following 6 weeks chemotherapy, an...
Patients with recurrent or metastatic neuroendocrine neoplasms (NEN) had a poor prognosis and few treatment options. Toripalimab, humanized IgG4 antibody specific for human PD-1 receptor, was first approved to treat second-line melanoma in China 2018.The multiple-center phase Ib trial enrolled patients NENs (Ki-67 ≥ 10%) after failure of first-line therapy received 3 mg/kg toripalimab once every two weeks. The primary objective response rate (ORR) safety. PD-L1 expression whole-exome...
Hepatoid adenocarcinoma of the stomach (HAS) is characterized by histological resemblance to hepatocellular carcinoma and a poor prognosis. The aim this study elucidate clinicopathological molecular characteristics HAS.Forty-two patients with HAS who received gastrectomy were enrolled in study. Based on panel 483 cancer-related genes, targeted sequencing 24 22 clinical parameter-matched common gastric cancer (CGC) samples was performed. Prognostic factors for overall survival (OS)...
Despite the encouraging efficacy of anti-PD-1/PD-L1 immunotherapy in microsatellite-instability-high/deficient mismatch repair (MSI-H/dMMR) advanced gastrointestinal cancer, many patients exhibit primary or acquired resistance. Using multi-omics approaches, we interrogate gut microbiome, blood metabolome, and cytokines/chemokines with MSI-H/dMMR cancer (N = 77) at baseline during treatment. We identify a number microbes (e.g., Porphyromonadaceae) metabolites arginine) highly associated...
Abstract Radiotherapy, a widely used therapeutic strategy for esophageal squamous cell carcinoma (ESCC), is always limited by radioresistance of tumor tissues and side‐effects on normal tissues. Herein, signature based four core genes cyclic GMP‐AMP synthase‐stimulator interferon (cGAS‐STING) pathway, developed to predict prognosis assess immune infiltration, indicating that the cGAS‐STING pathway radiotherapy efficacy are closely intertwined in ESCC. A novel lipid‐modified manganese...
Abstract Squamous cell carcinomas (SCCs) are common and aggressive malignancies. Immune check point blockade (ICB) therapy using PD-1/PD-L1 antibodies has been approved in several types of advanced SCCs. However, low response rate treatment resistance common. Improving the efficacy ICB requires better understanding mechanism immune evasion. Here, we identify that SCC-master transcription factor TP63 suppresses interferon-γ (IFNγ) signaling. inhibition leads to increased CD8 + T infiltration...
To explore the value of systemic inflammatory markers as independent prognostic factors and extent these improve classification for patients with inoperable advanced or metastatic gastric cancer (GC) receiving palliative chemotherapy.We studied such circulating white blood cell count its components well that combined to form inflammation-based scores (Glasgow Prognostic Score (GPS), Neutrophil-Lymphocyte Ratio (NLR), Platelet Lymphocyte (PLR), Index (PI) Nutritional (PNI)) in 384 first-line...
Background Despite the great achievements made in immune-checkpoint-blockade (ICB) cancer therapy, there are no effective predictive biomarkers gastrointestinal (GI) cancer. Methods This study included 93 metastatic GI patients treated with ICBs. The first cohort comprising 73 were randomly assigned into discovery (n=44) and validation (n=29) cohorts. Comprehensive genomic profiling was performed on all samples to determine tumor mutational burden (TMB) copy-number alterations (CNAs). A...
Cross-device interaction between multiple mobile devices is a popular field of research in HCI. However, the appropriate design this still an open question, with competing approaches such as spatially-aware vs. spatially-agnostic techniques. In paper, we present results two-phase user study that explores space: phase 1, elicited gestures for typical cross-device tasks from 4 focus groups (N=17). The show 71% were and participants strongly associated interacting thinking space. 2, implemented...
Overcoming tumor heterogeneity is a major challenge for personalized treatment of gastric cancer, especially human epidermal growth factor receptor‐2 targeted therapy. Analysis circulating DNA allows more comprehensive analysis than traditional biopsies in lung cancer and breast but little known cancer. We assessed mutation profiles ct primary tumors from 30 patients with advanced then performed mutations by multiple five patients, finally analyzed the concordance HER 2 amplification paired...
We compared efficacy and safety of paclitaxel/capecitabine therapy followed by capecitabine for maintenance (PACX) versus cisplatin/capecitabine (XP) in advanced gastric cancer. Multicenter, randomized, phase III trial was conducted China (December 2009–February 2014). Adults (n = 320) with histologically confirmed, untreated metastatic/unresectable or gastroesophageal junction adenocarcinoma; ≥ 1 measureable lesions according to Response Evaluation Criteria Solid Tumors 1.0 criteria;...